ArticleFrontiers in pharmacology2026
Serum potassium and high-altitude coronary microvascular disease: a propensity score matched analysis revealing a linear dose-response relationship.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-altitude exposure precipitates coronary microvascular disease (CMVD), a pathology linked to hypoxia-induced ion channel dysfunction. However, prior observational evidence connecting serum potassium to CMVD resilience is limited by residual confounding, and the precise dose-response trajectory remains unmapped. This study utilized Propensity Score Matching (PSM) to rigorously isolate this association and characterize the dose-response trajectory across the observed physiological range. Methods: We conducted a nested case-control analysis within a high-altitude training cohort. To minimize selection bias, 1:1 PSM was employed to strictly balance covariates-including age, blood pressure, and autonomic nervous regulation-between CMVD cases and controls. The final analytic sample comprised 462 participants (231 pairs). We applied conditional logistic regression and dose-response modeling to evaluate the association between pre-high-altitude serum potassium and CMVD risk. Results: Post-matching analysis confirmed that higher baseline serum potassium was independently associated with a significantly reduced CMVD likelihood. The adjusted odds ratio was 0.18 (95% CI: 0.08-0.42, Conclusion: Higher physiological serum potassium is robustly and linearly associated with reduced likelihood of CMVD under high-altitude hypoxic conditions. These association-based findings suggest the potential value of further investigating whether maintaining higher physiological potassium levels before high-altitude deployment may reduce CMVD risk, moving beyond merely screening for hypokalemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.